AbbVie has modified its business practices, including instituting remote work for many of its employees, in response to the ongoing COVID-19 pandemic, which has caused many countries to declare national emergencies and implement preventive measures. The extent of the adverse impact of COVID-19 on AbbVie's operations will depend on the severity of the continued spread of the virus globally and the timing and nature of actions taken to respond to it. AbbVie continues to closely manage manufacturing and supply chain resources around the world to ensure that patients receive an uninterrupted supply of their medicines. The company has experienced lower new patient starts across its therapeutic portfolio due to the pandemic, and it expects this matter could continue to negatively impact its results of operations. AbbVie has committed substantial effort, funds, and resources to research and development, which are critical for maintaining its competitive advantage and ensuring operational continuity. The integration plan following the acquisition of Allergan is designed to achieve more than $2 billion in expected annual cost synergies over a three-year period, with a focus on optimizing combined research and development, commercial, and manufacturing operations. The company's strategic objectives include maximizing the benefits of the Allergan acquisition to create a diversified revenue base and ensuring strong commercial execution of new product launches. AbbVie anticipates several regulatory submissions and key data readouts from clinical trials, which are essential for its resilience strategies and future planning. The company’s ability to adapt to changing market conditions and external pressures is reflected in its commitment to driving continued expansion of operating margins through revenue growth and realization of expense synergies. AbbVie’s reliance on third-party service providers and suppliers introduces additional complexities and risks, which could impact its operational flexibility and resilience. The company recognizes that significant safety or efficacy issues could arise for its products, which may adversely affect its revenues and financial condition. AbbVie is subject to numerous governmental regulations, and compliance with these regulations is critical for maintaining operational integrity and resilience. The company's financial flexibility is essential for responding to competitive pressures and ensuring the successful development and commercialization of its products. AbbVie’s strategic response to environmental disruptions and its focus on innovation are key components of its organizational resilience, enabling it to confront challenges and maintain performance under pressure. The successful integration of Allergan’s assets and capabilities into AbbVie’s existing framework is crucial for enhancing its organizational strength and ensuring long-term sustainability. The company’s commitment to learning and adapting through its research and development efforts reflects its understanding of the importance of organizational learning processes in navigating complex situations and ensuring future success.